银屑病关节炎的危害、诊治现状

doi:10.16150/j.1671-2870.2018.03.002

摘要/Abstract

中图分类号:

R758.63

戴生明. 银屑病关节炎的危害、诊治现状[J]. 诊断学理论与实践, 2018, 17(03): 238-243.

[1] Parisi R, Symmons DP, Griffiths CE, et al.Global epidemiology of psoriasis: a systematic review of incidence and prevalence[J]. J Invest Dermatol,2013,133(2):377-385.
[2] Ogdie A, Weiss P.The Epidemiology of Psoriatic Arthritis[J]. Rheum Dis Clin North Am,2015,41(4):545-568.
[3] Moll JM, Wright V.Psoriatic arthritis[J]. Semin Arthritis Rheum,1973,3(1):55-78.
[4] Gladman DD, Shuckett R, Russell ML, et al.Psoriatic arthritis (PSA)--an analysis of 220 patients[J]. Q J Med,1987,62(238):127-141.
[5] Caso F, Del Puente A, Oliviero F, et al.Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study[J]. Clin Rheumatol,2018,37(3):579-586.
[6] Polachek A, Touma Z, Anderson M, et al.Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies[J]. Arthritis Care Res (Hoboken),2017,69(1):67-74.
[7] Wong K, Gladman DD, Husted J, et al.Mortality studies in psoriatic arthritis: results from a single outpatient cli-nic. I. Causes and risk of death[J]. Arthritis Rheum,1997, 40(10):1868-1872.
[8] Reich K, Krüger K, Mössner R, et al.Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis[J]. Br J Dermatol,2009,160(5):1040-1047.
[9] Spelman L, Su JC, Fernandez-Peñas P, et al.Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice[J]. J Eur Acad Dermatol Venereol,2015,29(11):2184-2191.
[10] Mease PJ, Gladman DD, Papp KA, et al.Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics[J]. J Am Acad Dermatol,2013,69(5):729-735.
[11] Villani AP, Rouzaud M, Sevrain M, et al.Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis[J]. J Am Acad Dermatol,2015,73(2):242-248.
[12] Sørensen J, Hetland ML, all departments of rheumatology in Denmark. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry[J]. Ann Rheum Dis,2015,74(3):e12.
[13] Payet J, Goulvestre C, Bialé L, et al.Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1 162 patients[J]. J Rheumatol,2014,41(12):2395-2402.
[14] Taylor W, Gladman D, Helliwell P, et al.Classification criteria for psoriatic arthritis: development of new criteria from a large international study[J]. Arthritis Rheum,2006, 54(8):2665-2673.
[15] Poggenborg RP, Østergaard M, Terslev L.Imaging in Psoriatic Arthritis[J]. Rheum Dis Clin North Am,2015, 41(4):593-613.
[16] Palazzi C, Lubrano E, D'Angelo S, et al. Beyond early diagnosis: occult psoriatic arthritis[J]. J Rheumatol,2010, 37(8):1556-1558.
[17] Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis[J]. Ann Rheum Dis,2015,74(6):1045-1050.
[18] Roubille C, Richer V, Starnino T, et al.The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis[J]. Ann Rheum Dis,2015,74(3):480-489.
[19] Coates LC, Kavanaugh A, Mease PJ, et al.Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis[J]. Arthritis Rheumatol,2016,68(5):1060-1071.
[20] Gossec L, Smolen JS, Ramiro S, et al.European League Against Rheumatism(EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update[J]. Ann Rheum Dis,2016,75(3):499-510.
[21] 戴生明. 银屑病关节炎的治疗[M]// 戴生明. 银屑病关节炎. 北京: 人民卫生出版社,2018:257-287.
[22] Kingsley GH, Kowalczyk A, Taylor H, et al.A randomi-zed placebo-controlled trial of methotrexate in psoriatic arthritis[J]. Rheumatology (Oxford),2012,51(8):1368-1377.
[23] Smolen JS, Schöls M, Braun J, et al.Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force[J]. Ann Rheum Dis,2018,77(1):3-17.
[24] Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial[J]. Lancet,2015,386(10012):2489-2498.
[25] Coates LC, Fransen J, Helliwell PS.Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment[J]. Ann Rheum Dis,2010,69(1):48-53.
[26] Schoels MM, Aletaha D, Alasti F, et al.Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score[J]. Ann Rheum Dis,2016,75(5):811-818.
[27] Mease PJ, Genovese MC, Greenwald MW, et al.Brodalumab, an anti-IL17RA monoclonal antibody, in psoria-tic arthritis[J]. N Engl J Med,2014,370(24):2295-2306.
[28] Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixeki-zumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase Ⅲ trial SPIRIT-P1[J]. Ann Rheum Dis,2017,76(1):79-87.
[29] Kavanaugh A, Ritchlin C, Rahman P, et al.Ustekinu-mab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials[J]. Ann Rheum Dis,2014,73(6):1000-1006.
[30] Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase Ⅲ study in psoriatic arthritis[J]. Ann Rheum Dis,2017,76(9):1550-1558.
[31] Edwards CJ, Blanco FJ, Crowley J, et al.Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoria-tic arthritis and current skin involvement: a phase Ⅲ, randomised, controlled trial(PALACE 3)[J]. Ann Rheum Dis,2016,75(6):1065-1073.
[32] Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adali-mumab versus Placebo for Psoriatic Arthritis[J]. N Engl J Med,2017,377(16):1537-1550.

银屑病关节炎的危害、诊治现状

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何亲羽, 王伟, 陈立芬, 张雪蕾, 董治亚. LHCGR基因突变致家族性男性性早熟2例报告及文献复习[J]. 诊断学理论与实践, 2022, 21(05): 598-605.
[2]	陈志敏, 何浩岚. 艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430.
[3]	沈银忠. 《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读[J]. 诊断学理论与实践, 2022, 21(04): 431-436.
[4]	施霞, 马鑫, 王珍燕, 张晖, 刘少军. 32例人类免疫缺陷病毒感染合并慢性肾病患者的临床病理特征及随访结果分析[J]. 诊断学理论与实践, 2022, 21(04): 437-443.
[5]	陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[6]	何新, 陈慧, 冯炜炜. 机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546.
[7]	徐子真, 李擎天, 刘湘帆, 李莉, 李惠, 王也飞, 吴洁敏, 陈宁, 梁璆荔, 陈松立, 戴健敏, 宋珍, 丁磊. 实验诊断学在线课程的建立和实践[J]. 诊断学理论与实践, 2022, 21(04): 547-550.
[8]	李佳, 吕良敬. 靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.
[9]	赵然, 詹维伟, 侯怡卿. 计算机辅助诊断系统辅助超声诊断甲状腺弥漫性病变合并结节良恶性的应用价值[J]. 诊断学理论与实践, 2022, 21(03): 390-394.
[10]	郭业兵, 郑金峰. 阴道壁胃肠道外间质瘤一例报道并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 405-407.
[11]	中华医学会内分泌学分会. 新型冠状病毒肺炎疫情下骨质疏松症管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 133-135.
[12]	王刚, 陈生弟. 神经病学的诊断：起源、发展及挑战[J]. 诊断学理论与实践, 2022, 21(01): 1-4.
[13]	唐静仪, 余群, 刘军. 结合人工智能的结构影像分析对阿尔茨海默病的早期预测及精准诊断研究进展[J]. 诊断学理论与实践, 2022, 21(01): 12-17.
[14]	魏文石. 直面我国阿尔茨海默病诊治的挑战——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 5-7.
[15]	王蔚, 王小钦. 缺铁性贫血的病因诊断[J]. 诊断学理论与实践, 2021, 20(06): 529-532.